🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 18/05/2005 | 13,38 | 14,05 | 13,22 | 13,70 | +3,79% | 6,20% | 3.738.800 |
| 17/05/2005 | 12,90 | 13,37 | 12,50 | 13,20 | +1,69% | 6,74% | 2.545.900 |
| 16/05/2005 | 12,80 | 13,20 | 12,25 | 12,98 | +1,49% | 7,42% | 1.435.900 |
| 13/05/2005 | 13,36 | 13,62 | 12,71 | 12,79 | -4,48% | 6,81% | 1.956.700 |
| 12/05/2005 | 13,45 | 13,93 | 13,19 | 13,39 | -0,07% | 5,50% | 3.053.000 |
| 11/05/2005 | 13,52 | 13,60 | 12,77 | 13,40 | +0,00% | 6,14% | 5.647.700 |
| 10/05/2005 | 12,63 | 13,82 | 12,13 | 13,40 | +19,75% | 13,38% | 23.060.200 |
| 09/05/2005 | 10,73 | 11,27 | 10,65 | 11,19 | +5,07% | 5,78% | 784.100 |
| 06/05/2005 | 10,03 | 10,67 | 9,87 | 10,65 | +6,50% | 7,98% | 696.500 |
| 05/05/2005 | 9,68 | 10,00 | 9,58 | 10,00 | +3,41% | 4,34% | 458.100 |
| 04/05/2005 | 9,65 | 9,73 | 9,50 | 9,67 | +1,04% | 2,38% | 488.400 |
| 03/05/2005 | 9,40 | 9,68 | 9,33 | 9,57 | +1,59% | 3,72% | 386.800 |
| 02/05/2005 | 9,58 | 9,75 | 9,20 | 9,42 | -1,15% | 5,74% | 517.500 |
| 29/04/2005 | 9,19 | 9,59 | 9,03 | 9,53 | +3,70% | 6,09% | 397.200 |
| 28/04/2005 | 9,48 | 9,51 | 9,09 | 9,19 | -2,75% | 4,43% | 500.100 |
| 27/04/2005 | 9,55 | 9,91 | 9,27 | 9,45 | -1,25% | 6,70% | 508.100 |
| 26/04/2005 | 9,98 | 10,04 | 9,22 | 9,57 | -3,92% | 8,22% | 835.800 |
| 25/04/2005 | 9,72 | 9,98 | 9,68 | 9,96 | +2,79% | 3,09% | 333.400 |
| 22/04/2005 | 9,83 | 9,83 | 9,45 | 9,69 | -0,51% | 3,87% | 387.200 |
| 21/04/2005 | 9,30 | 9,80 | 9,30 | 9,74 | +4,96% | 5,38% | 487.400 |
| 20/04/2005 | 9,55 | 9,55 | 9,12 | 9,28 | -1,90% | 4,50% | 559.700 |
| 19/04/2005 | 9,57 | 9,65 | 9,38 | 9,46 | -0,94% | 2,82% | 490.200 |
| 18/04/2005 | 9,59 | 9,77 | 9,32 | 9,55 | -0,21% | 4,69% | 499.400 |
| 15/04/2005 | 9,35 | 9,87 | 9,35 | 9,57 | +0,63% | 5,56% | 645.700 |
| 14/04/2005 | 9,62 | 9,79 | 9,47 | 9,51 | -1,35% | 3,33% | 318.100 |
| 13/04/2005 | 10,09 | 10,16 | 9,55 | 9,64 | -4,84% | 6,05% | 487.300 |
| 12/04/2005 | 9,95 | 10,16 | 9,43 | 10,13 | +1,00% | 7,34% | 567.500 |
| 11/04/2005 | 10,00 | 10,19 | 9,91 | 10,03 | +0,30% | 2,80% | 494.300 |
| 08/04/2005 | 9,98 | 10,15 | 9,95 | 10,00 | +0,40% | 2,00% | 721.700 |
| 07/04/2005 | 9,60 | 9,96 | 9,46 | 9,96 | +4,84% | 5,21% | 611.100 |